who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

BDX · Q3 FY2026

Archived report (Q3 FY2026). Latest deep dive →

US GAAP, Q3 FY26 · quarter ended 06/30/2026 (fiscal year is shifted) · released Aug 6

Net Income

$377M

down 34.3% y/y

Revenues

$4,983M

up 5.4% y/y

Operating Income

$663M

down 10.3% y/y

The quarter in brief

BD's revenue rose 5.4% to $4.98B, but operating income fell 10.3% to $663M and net income dropped 34.3% to $377M.

All figures in $M.

Sankey diagram of BDX earnings report for Q3 FY2026: revenue, costs and profitRevenues$4,983 · +5.4%Cost of productssold$2,668 · +7.1%Selling andadministrativeexpense$1,261 · +8.4%Research anddevelopmentexpense$258 · +12.2%Integration,restructuring andtransactionexpense$89 · −7.3%Other operatingexpense, net$44 · +529%Operating Income$663 · −10.3%13.3% marginInterest expense$132 · −13.2%Interest income$4 · +0.0%Other income(expense), net$19 · vs −$22Income fromContinuingOperations BeforeIncome Taxes$554 · −2.6%Income tax provision$102 · −13.6%18.4% effective rate(Loss) Income fromDiscontinued Operations,Net of Tax$74 · vs $123Net Income$377 · −34.3%$1.37/sh · 7.6% margin
Sankey diagram of BDX earnings report for Q3 FY2026: revenue, costs and profit
Line itemAmount and change
Revenues$4,983 · +5.4%
Cost of products sold$2,668 · +7.1%
Selling and administrative expense$1,261 · +8.4%
Research and development expense$258 · +12.2%
Integration, restructuring and transaction expense$89 · −7.3%
Other operating expense, net$44 · +529%
Operating Income$663 · −10.3% · 13.3% margin
Interest expense$132 · −13.2%
Interest income$4 · +0.0%
Other income (expense), net$19 · vs −$22
Income from Continuing Operations Before Income Taxes$554 · −2.6%
Income tax provision$102 · −13.6% · 18.4% effective rate
(Loss) Income from Discontinued Operations, Net of Tax$74 · vs $123
Net Income$377 · −34.3% · $1.37/sh · 7.6% margin

Verdict: BD's revenue rose 5.4% to $4.98B, but operating income fell 10.3% to $663M and net income dropped 34.3% to $377M.

Source and notation

Source: BDX press release, 8-K EX-99.1 of 08/06/2026 (SEC EDGAR).

Open as an image: BDX, Q3 FY2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “BDX Q3 FY2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/bdx/q3-fy2026. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/bdx/q3-fy2026"><img src="https://whoreportstoday.com/t/bdx/q3-fy2026/sankey.png" alt="BDX Q3 FY2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/bdx/q3-fy2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/bdx/q3-fy2026/sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/bdx/q3-fy2026">BDX Q3 FY2026 earnings chart (Who Reports Today)</a>

This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

BDX — a medical technology company that develops, makes and sells medical supplies, devices, laboratory equipment and diagnostic products to hospitals, physicians, clinical laboratories, researchers and drugmakers.

As of its fiscal 2025 report it had three worldwide segments: BD Medical, BD Life Sciences and BD Interventional. · Source: annual report (Form 10-K, SEC)

Heads-up

More reports: BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q4 FY2026 · CRL · Q3 2026 · CVS · Q3 2026 · all reports

Company reports

Q4 FY2026latest breakdownIn the fourth quarter of fiscal 2026 BD's revenue rose 5.4% to $5,274 million and operating income increased to $1,032…
Q3 FY2026BD's revenue rose 5.4% to $4.98B, but operating income fell 10.3% to $663M and net income dropped 34.3% to $377M.

Cookies the site needs and, with your consent, Google Analytics — privacy policy